This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Mar 19, 2026
•
8 min read
🧬 Crossbow Therapeutics raises $77M Series B - developing next-generation cancer immunotherapies, TerraPower commits $450M to build Philadelphia radioisotope production plant - boosting actinium-225 capacity 20-fold, Johnson & Johnson's Icotyde (icotrokinra) wins FDA approval for moderate-to-severe plaque psoriasis targeting interleukin-23
Mar 18, 2026
🧬 BioVie’s Option Therapeutics plans $20M IPO - developing liver disease drug treatment, R1 Therapeutics emerges with $77.5M series A funding for novel CKD phosphate control drug AP306, Pfizer's atirmociclib hits Ph2 goal reducing death risk 40% in advanced breast cancer patients
Mar 17, 2026
🧬 Roche + Nvidia expand AI partnership with 2,176 Blackwell GPUs for drug and diagnostic development, Federal judge blocks RFK Jr.'s childhood vaccine schedule changes + halts CDC advisory panel appointments, Unnatural Products raises $45M Series B, macrocyclic peptides for undruggable targets, CytomX Therapeutics reports positive Ph1 data for Varseta-M antibody-drug conjugate in colorectal cancer, Eli Lilly's Ebglyss IL-13 inhibitor hits Ph3 endpoints in pediatric atopic dermatitis - setting up label expansion, AstraZeneca's Imfinzi (durvalumab) wins EU approval for resectable gastric and gastroesophageal junction cancers following Ph3 success
Mar 16, 2026
6 min read
🧬 Sana Biotechnology's UP421 islet cell therapy shows sustained insulin production at 14 months in Type 1 diabetes patient, Gubra launches Gubra Ventures unit to incubate new biotechs using Roivant-like asset-centric company model, GSK's Arexvy wins FDA label expansion for respiratory syncytial virus in high-risk adults under 50
Mar 13, 2026
7 min read
🧬 Eli Lilly invests $126M to expand Japan manufacturing plant for diabetes and obesity medicines, Regenxbio reports positive Ph1/Ph2 data for RGX-202 gene therapy in Duchenne muscular dystrophy, Enodia Therapeutics pays for Kezar Life Sciences preclinical protein degrader program - $1M upfront + $127M milestones
Mar 12, 2026
9 min read
🧬 FDA launches unified Adverse Event Monitoring System replacing fragmented databases - saving $120M over five years, Eli Lilly invests $3B in China operations to boost orforglipron weight loss pill manufacturing capacity, Salspera plans $91M IPO to fund phase 3 salmonella-based cancer therapy studies, Vima Therapeutics raises $100M Series B - oral drug for movement disorders, UCB's Bimzelx (bimekizumab) shows Ph3 superiority over AbbVie's Skyrizi in psoriatic arthritis head-to-head trial
Mar 11, 2026
🧬 Breakout Ventures raises $114M third fund - supporting AI-focused early-stage biotechs, CSL breaks ground on $1.5B plasma medicine plant expansion in Illinois - creating 300 jobs by 2031, GSK's Wellcovorin (leucovorin) wins FDA approval for cerebral folate deficiency targeting folate receptor 1
Mar 10, 2026
🧬 Novo Nordisk + Hims & Hers partner to sell GLP-1 drugs Ozempic and Wegovy, ending lawsuit dispute, Alfasigma + GSK strike $690M deal for linerixibat itching treatment awaiting FDA approval, Regeneron Pharmaceuticals reports positive Ph3 data for olatorepatide (olatorepatide) targeting GLP-1/GIP receptors for obesity treatment, Relmada Therapeutics raises $160M private placement, advancing oncology and CNS therapies, FDA's Prasad departure boosts rare disease biotechs uniQure, Replimune, Disc Medicine stock prices premarket Monday
Mar 9, 2026
🧬 Servier acquires Day One Biopharmaceuticals for $2.5B to expand childhood brain tumor portfolio with Ojemda, Sanofi + EMS strike deal to sell generics manufacturer Medley for above $500M, Pfizer's Xianyida (ecnoglutide) wins China approval for obesity treatment targeting GLP-1 receptor following Ph3 results
Mar 6, 2026
🧬 Portal Innovations to open 30,000-square-foot biotech incubator in Salt Lake City by 2027, Zealand Pharma's petrelintide shows placebo-like tolerability with 10.7% weight loss in Ph2 obesity trial, BioDuro + Cenra API Solutions form Taiwan joint venture for end-to-end API manufacturing services
Mar 5, 2026
🧬 Roche invests $484M in South Korea to establish global clinical trial ecosystem, Ireland maintains biopharma investment appeal despite US tariff uncertainty and geopolitical trade tensions, UK invests $64M in NHS equipment to expand clinical trial access to underserved communities, ARPA-H launches $158M program for first-ever lymphatic system drug development, Blackstone Life Sciences + Teva Pharmaceutical partner on gut disease drug duvakitug with $400M commitment, Nvidia, Droplet Biosciences partner on AI-accelerated genomic analysis for lymph-based liquid biopsy testing
Mar 4, 2026
20 min read
🧬 Novo Nordisk commits $506M to upgrade Irish facility for oral Wegovy production ahead of European approval, Alveus Therapeutics raises $37M Series A extension for obesity drug development, Atrium Therapeutics spins out of Novartis-acquired Avidity with $270M to develop RNA medicines for rare heart diseases, Roche's fenebrutinib (BTK inhibitor) hits Ph3 goals in relapsing multiple sclerosis despite safety concerns, Sanofi + Sino Biopharmaceutical license JAK/ROCK inhibitor rovadicitinib globally, $135M upfront +$1.53B total, Earendil Labs + WuXi XDC partner on next-gen ADC linker technology + $885M total deal, Moderna's mCombriax combination flu and COVID-19 vaccine wins European drug regulators' positive recommendation for ages 50+
